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Abstract 
Perivascular adipose tissue (PVAT) is now recognised as an active player in vascular homeostasis. 
Expansion of PVAT in obesity and the possible role of PVAT in vascular dysfunction has attracted 
much interest. In terms of the regulation of vascular tone and blood pressure, PVAT has been shown 
to release vasoactive mediators, for instance angiotensin peptides, reactive oxygen species, 
chemokines and cytokines. The secretory profile of PVAT is altered by obesity, hypertension and 
other cardiovascular diseases, leading to imbalance between its pro-contractile and anti-contractile 
effects. PVAT adipocytes represent an important source of the mediators, but infiltrating immune 
cells may become more important under conditions of hypoxia and inflammation. This review 
describes recent advances on the effects of PVAT on vascular tone regulation, highlighting the 
evidence for a pro-contractile action in health and disease. The role of the endothelium, vascular 
smooth muscle, immune cells and probably perivascular nerves in PVAT function is also discussed.  
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These Tables of Links list key protein targets and ligands in this article that are hyperlinked* to 
corresponding entries in http://www.guidetopharmacology.org, the common portal for data from 
the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016), and are permanently archived in 
The Concise Guide to PHARMACOLOGY 2015/16 (a,b,c,dAlexander et al., 2015a,b,c,d). 
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Introduction  
Perivascular adipose tissues (PVAT) were originally thought to only provide structural support and 
thus routinely removed in vessel contractility studies. However, the growing prevalence of obesity, 
characterised by excessive adipose tissues, and the realisation that adipose tissues act as a complex 
paracrine and endocrine organ (Gustafson et al., 2007; Ahima & Flier, 2000) has drawn attention to a 
functional role of PVAT, which might also provide a mechanistic link between obesity and vascular 
dysfunction. PVAT is now recognised as a specialised fat depot around most blood vessels, releasing 
diffusible factors that modulate local vascular reactivity and inflammatory status and, as a result, 
may contribute to pathophysiological changes seen in cardiovascular diseases, diabetes and obesity 
(reviewed in, Szasz et al., 2013; Yudkin et al., 2015; Gil-Ortega et al., 2015; Fernandez Alfonso et al., 
2017). Indeed, the Framingham Heart Study shows that a higher volume of PVAT around thoracic 
aorta is associated with metabolic risk factors and higher prevalence of cardiovascular disease in 
volunteers (Lehman et al., 2010; Britton et al., 2012). Numerous mechanisms have been suggested 
to underlie the cross talk between PVAT and vascular cells, but the regulation of PVAT function, 
particularly the balance between its beneficial and deleterious effects remains poorly defined. In 
1991, Soltis and Cassis reported that, in rat aorta, PVAT potentiated contractions to a 
sympathomimetic but reduces that to noradrenaline due to reuptake by adrenergic nerves in PVAT. 
Subsequently, PVAT was also found to reduce responses to other vasoconstrictors, leading to the 
proposal of PVAT-derived (PVRFs) or adipocyte-derived relaxing factors (ADRFs). Much of the 
research has since focused on identifying these relaxing factors and establishing their vascular 
actions (see Gollasch, 2012 and Withers et al., 2014 for reviews). However, there is also evidence for 
the production of contractile factors from PVAT, which were initially termed perivascular adipocyte-
derived contractor factors (PVCFs; Gao, 2007) and later adipocyte-derived contractile factors (ADCFs; 
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Meyer et al., 2013). This adds to a complex scenario of anti-contractile vs pro-contractile properties 
of PVAT. In this review, we intend to provide an update on the balance between relaxant and 
contractile effects of PVAT, highlighting a potential shift from an anti-contractile action of PVAT in 
health to a pro-contractile action in obesity and related cardiovascular diseases.  
 
Composition of PVAT 
Adipose tissue surrounding blood vessels is not physically separated from the vascular wall by a 
fascial layer, providing access for its paracrine effects. In general, brown adipocytes are larger in size, 
with smaller oil droplets and larger numbers of mitochondria than white adipocytes, which store 
triglycerides. Morphological and gene expression analysis indicate that whilst perivascular 
adipocytes often resemble white adipocytes, they are distinct from visceral and subcutaneous fat 
and display characteristics of both white and brown adipocytes; sometimes referred to as beige 
adipocytes. For instance, perivascular adipocytes of human coronary arteries are smaller and 
irregularly shaped, with fewer differentiation markers but higher expression of some brown 
adipocyte-related genes, when compared to subcutaneous adipocytes (Chatterjee et al., 2009). The 
precise phenotype appears to depend on the vascular region and species (Szasz et al., 2013; Gil-
Ortega et al., 2015). Adipocytes around thoracic aorta are more similar to brown adipocytes, at least 
in rodents (Gálvez-Prieto et al., 2008a; Padilla et al., 2013). However, adipocytes from abdominal 
aorta and mesenteric arteries are closer to white adipocytes in both rodents and humans (Henrichot 
et al., 2005; Police et al., 2009; Padilla et al., 2013).  
Importantly, adipose tissues are dynamically regulated, showing cellular and metabolic 
plasticity. Sustained obesity is associated with increases in size and/or number of PVAT white 
adipocytes (Marchesi et al., 2009; Ketonen et al., 2010; Ma et al., 2010; Greenstein et al., 2009). 
These are accompanied by functional changes, including altered secretion pattern of PVAT 
(Greenstein et al., 2009; Chatterjee et al., 2009; Ketonen et al., 2010). On the other hand, increased 
proportion of brown to white adipocytes (browning of adipose tissues) promotes thermogenesis and 
might represent a protective mechanism against metabolic diseases (Pellegrinelli et al., 2016), and 
perhaps improve vascular function in obesity and atherosclerosis (Fitzgibbons et al., 2011; Chang et 
al., 2012).    
 In addition to adipocytes, PVAT contains other important cell types such as macrophages, T-
lymphocytes and fibroblasts, which may also contribute to PVAT function. Indeed, infiltration of 
immune cells in PVAT is characteristic of disease states associated with vascular inflammation (Omar 
et al., 2014; Pellegrinelli et al., 2016). Expansion of PVAT also likely involves generation of pre-
adipocytes from resident mesenchymal stem cells and maturation of pre-adipocytes (Pellegrinelli et 
al., 2016). Moreover, PVAT is also innervated by sympathetic nerves (Bulloch and Daly, 2014; Darios 
et al., 2016), which could stimulate the browning of PVAT. Nonetheless, the interactions among 
perivascular adipocytes, immune cells and nerves in vascular regulation remain poorly defined. 
Adipocytes, which are the main cellular component of PVAT, are known to release vasoactive 
substances (e.g. ADRF and ADCF), but immune cells and sympathetic nerves might serve as 
additional sources (e.g. Gao et al., 2006; Lumeng et al., 2007; Dashwood and Loesche, 2011; Nguyen 
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et al., 2011). Where possible, we will highlight the likely cellular source(s) of vasoactive substances 
within PVAT.  
 
Evidence for contractile factors from PVAT 
Similar to adipocytes in other anatomical locations, increasing evidence suggests that PVAT secretes 
bioactive molecules, including adipokines and other cytokines that regulate cardiovascular function. 
A number of these diffusible factors can induce direct vasocontraction, and maybe referred to as 
PVAT-derived or adipocyte-derived contractor factors (denoted ADCFs herein), which are highlighted 
in Table 1. Much of the evidence comes from contractility studies using isolated arteries with and 
without PVAT, combined with isolated PVAT and its conditioned media under physiological 
conditions. 
Adipocytes are known to express a local renin-angiotensin-aldosterone system (RAAS), 
including angiotensinogen and angiotensin converting enzyme for synthesis of the potent 
vasoconstrictor, angiotensin II (Ang II; Cassis et al., 2008; Karlsson et al., 1998). The expression of 
RAAS components can vary depending on the composition and location of adipose tissues (Cassis et 
al., 1988; Engeli et al., 1999; Galvez-Prieto et al., 2008a; Riedel et al., 2016). PVAT is thought to 
express all components of RAAS and that PVAT-derived Ang II promotes contractions through AT1 
receptor activation in rat mesenteric arteries (Lu et al., 2010). Gao and co-workers proposed that 
Ang II acts indirectly by stimulating superoxide radical production from NADPH oxidase in PVAT 
adipocytes or the vascular wall itself (Gao et al., 2006; Lu et al., 2008). Ang II has also been shown to 
play a role in local inflammation associated with hypertension and obesity, stimulating infiltration of 
immune cells including T-lymphocytes and macrophages in PVAT and production of reactive oxygen 
species (Police et al., 2009; Guzik et al., 2007; Mikolajczyk et al., 2016). However, the importance of 
PVAT as a source of Ang II in the control of vascular tone and blood pressure, particular in 
hypertension and obesity, remains to be established. Moreover, it is likely that the production and 
function of PVAT-derived Ang II show regional heterogeneity (Galvez-Prieto et al., 2008a). Ang II can 
also further exacerbate PVAT dysfunction, since AT1 receptor activation has been shown to reduce 
browning of adipose tissue, and promote adipocyte hypertrophy, insulin resistance and weight gain 
in high fat-induced obesity in mice (Graus-Nunes et al., 2017).  
 In the initial study by Soltis and Cassis (1991), PVAT greatly enhanced contractions to 
electrical field stimulation or the indirect sympathomimetic tyramine in rat aorta, suggesting a role 
for sympathetic nerve activity in PVAT. Sympathetic nerves have been reported in PVAT of human 
saphenous veins (Dashwood and Loesche, 2011). The role for sympathetic innervation in the 
regulation of vascular tone and blood pressure is well established. Elevated sympathetic activity is 
also associated with hypertension, including obesity-associated hypertension (Thalmann and Meier, 
2007), however the interaction between PVAT and local sympathetic activity in healthy and disease 
conditions has not been scrutinised. Sympathetic activity and subsequent release of catecholamines 
are known to regulate lipolysis, and proliferation and differentiation of adipocytes activation 
through α- and β-adrenoceptors. Recent evidence has also suggested that adipocytes and 
alternatively activated macrophages in adipose tissues may synthesize and release noradrenaline 
and adrenaline (Vargovic et al., 2011; Nguyen et al., 2011). In thoracic aorta and superior mesenteric 
arteries, where PVAT enhances contraction via α1-adrenoceptors, noradrenaline and its synthetic 
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enzymes are detected in PVAT adipoctyes (Ayala-Lopez et al., 2014). PVAT-dependent contractions 
to the sympathomimetic tyramine have also been reported in the same large arteries (Soltis and 
Cassis, 1991; Ayala-Lopez et al., 2014). Tyramine is traditionally used to release catecholamines from 
sympathetic nerve endings, but the possibility of an action on adipocytes or immune cells in PVAT 
cannot be excluded.  
Another factor that may contribute to the contractile effects of PVAT is the adipokine, 
chemerin (Table 1). Chemerin, in particular chemerin-9, evokes direct vasocontraction and enhances 
agonist-induced contractions via its G-protein-coupled receptor, ChemR23 in rat and human arteries. 
Moreover, these effects are exaggerated in thoracic aorta and mesenteric arteries with reduced 
endothelium-dependent relaxation, a phenomenon often found in hypertension and obesity (Watts 
et al., 2013). A follow-up study by the same group (Darios et al., 2016) has also shown that PVAT-
derived chemerin potentiates sympathetic contraction through ChemR23, which is co-localised with 
tyrosine hydrolase in sympathetic nerves of rat superior mesenteric artery. Direct application of 
chemerin to isolated aorta or mesenteric artery also augments agonist-induced contraction in a 
manner dependent on endothelin ETA receptor and ERK activation (Lobato et al., 2012), and 
increases systolic blood pressure in mice (Kunimoto et al., 2015). Thus, chemerin might play a 
particularly important role in some forms of hypertension and obesity. 
 In addition to chemerin, cytokines derived from PVAT might also increase vascular tone. For 
instance, tumour necrosis factor- (TNF) and interleukin-6 (IL-6) are known to enhance 
contractions, probably via upregulation of endothelin signalling or reduced nitric oxide (NO) 
production and endothelium-dependent relaxation, especially in obese patients (Greenberg et al., 
1985; Orshal and Khalil, 2004; Virdis et al., 2015). High-fat diet has also been shown to promote IL-6 
expression in human coronary PVAT (Chatterjee et al., 2009). 
Aortic and small mesenteric PVAT also release contractile cyclooxygenase (COX) products, 
including thromboxane A2 (TXA2) and PGE2 (Meyer et al., 2013; Mendizabal et al., 2013). In the same 
vascular regions, contraction to prostanoids and their receptor expression are enhanced in obese 
mice (Traupe et al., 2002) or diabetic rats (Ishida et al., 2012). Interestingly, however, a significant 
amount of PVAT-derived TXA2 and PGE2 are also detected in healthy controls suggesting a possible 
physiological role (Meyer et al., 2013). Prostanoids might also mediate PVAT-induced endothelial 
dysfunction in both normotensive and hypertensive rats (Mendizabal et al., 2013), contributing to a 
pro-contractile effect of PVAT. It remains to be clarified how the secretory pattern of various 
prostanoids is altered in pathophysiological conditions.  
Taken together, PVAT is capable of releasing multiple contractile factors, which elicit direct 
vasocontraction, or enhance nerve- or agonist-mediated contractions by acting on the vascular 
smooth muscle. These factors appear, at least partly, active in healthy conditions especially in larger 
arteries. Previous studies have reported elevated systemic levels of angiotensin II, superoxide, 
catecholamines, contractile prostanoids, TNFα, chemerin and leptin in hypertension, diabetes or 
obesity (Brunner et al., 2005; Gu et al., 2015), but PVAT is yet to be established as a major source of 
these mediators. There is however evidence pointing to increased responsiveness to chemerin, TNFα 
and prostanoids in aorta and resistance arteries (Watts et al., 2013; Meyer et al., 2013; Traupe et al., 
2002; Ishida et al., 2012; Virdis et al., 2015). In addition to acute vasocontraction, sustained 
elevation of some of the ADCF, such as superoxide, Ang II and TNFα, might stimulate vascular 
smooth muscle growth and arterial stiffness (Fleenor et al., 2014; Almabrouk et al., 2014; Kunimoto 
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et al., 2015; Noblet et al., 2016; also reviewed by Miao & Li, 2012, Aroor et al., 2013 and Villacorta & 
Chang, 2015), commonly found in atherosclerosis, hypertension and ageing. In line with this, PVAT 
expression of chemerin is positively correlated with atherosclerosis in human aorta and coronary 
artery (Spiroglou et al., 2010). The vascular remodelling effect of PVAT is also associated with 
endothelial dysfunction, a hallmark of cardiovascular diseases. For vascular tone regulation, a 
reduction in endothelium-dependent relaxation would exaggerate the pro-contractile effects of 
PVAT and will be further explored in the following section.  
 
Evidence for PVAT-induced endothelial dysfunction  
The vascular endothelium is critical for maintaining cardiovascular homeostasis, and its dysfunction 
is considered an early sign or predictor of cardiovascular diseases, including those associated with 
obesity and diabetes (Brunner et al., 2005). Endothelial dysfunction can manifest, for example, as 
reduced endothelium-dependent relaxation, endothelium-dependent contraction, leukocyte 
adhesion and reduced anti-coagulation properties. In Table 2, we highlight some of the studies 
demonstrating the inhibitory effect of PVAT on responses to endothelium-dependent relaxants, 
which could enhance vasocontraction and might be particularly relevant to hypertension linked to 
obesity and diabetes. Where possible, the specific PVAT-derived mediators and disease conditions 
involved are also indicated in Table 2.  
A primary mechanism of action for PVAT is reduced NO production or bioavailability, 
although NO-independent signalling pathways may also be compromised. Given the physical 
distance between PVAT and the endothelium particularly in conduit arteries, it is thought that 
mediators released by PVAT are involved. They include NADPH oxidase-derived reactive oxygen 
species (superoxide, hydrogen peroxide) and pro-inflammatory cytokines (leptin, TNFα, IL-6, resistin, 
visfatin) (Payne et al., 2010; Ketonen et al., 2010; Marchesi et al., 2009; Greenstein et al., 2009; 
Vallejo et al., 2011; Aghamohammadzadeh et al., 2016). Importantly, targeting dysregulation of 
these PVAT factors, which accompanies adipocyte hypertrophy in obesity and metabolic syndrome 
can improve endothelial function (Marchesi et al., 2009; Aghamohammadzadeh et al., 2016). 
Circulating visfatin levels may also predict the extent of endothelium-dependent, flow-mediated 
dilation in patients with atherosclerosis and diabetes (Romacho et al., 2013). These findings support 
the clinical relevance of PVAT dysfunction in vascular health. Indeed, oxidative stress and increased 
production of pro-inflammatory cytokines, as well as endothelial dysfunction, have been closely 
linked to the pathophysiology of obesity, hypertension, atherosclerosis, and insulin resistance. 
On the other hand, PVAT can also reduce endothelium-independent relaxation. In many 
studies, the presence of PVAT has no significant effect on relaxation to NO donors (Payne et al., 
2008; Ma et al., 2010; Vallejo et al., 2011; Lee et al., 2014). However, Tune and co-workers (Owen et 
al., 2013; Noblet et al., 2015) have shown that PVAT inhibits distinct subtypes of K+ channels in 
coronary smooth muscle of lean versus diet-induced obese pigs. Another adipokine, nesfatin-1 has 
also been shown to reduce smooth muscle cGMP production in mesenteric arteries, and increase 
arterial blood pressure in rats (Yamawaki et al., 2012).  
 
 
  
This article is protected by copyright. All rights reserved. 
Evidence for relaxant factors from PVAT 
In contrast to the aforementioned (pro)contractile actions, numerous PVAT-derived mediators are 
vasorelaxants and therefore exert anti-contractile effects, which have been the focus of a number of 
excellent reviews (e.g. Gollasch, 2012 and Withers et al., 2014). PVAT relaxants include adiponectin, 
omentin, leptin, angiotensin 1-7 (Ang 1-7), NO, hydrogen peroxide and hydrogen sulphide (H2S) 
(Dubrovska et al., 2004; Gao et al., 2007; Lee et al., 2009; Payne et al., 2010; Gil-Ortega et al., 2010; 
Schleifenbaum et al., 2010). Again, isolated tension recording and bioassay experiments have been 
instrumental in establishing an anti-contractile action of PVAT in arteries from rodents and humans. 
Of note, the presence of PVAT reduces contraction to some, but not all, vasoconstrictors (Soltis and 
Cassis, 1991; Lohn et al., 2002; Verlohren et al. 2004; Gao et al., 2005b; Malinowski et al., 2008; 
Greenstein et al., 2009). Under physiological conditions, adipocytes are thought to be the main 
cellular source of these factors, which are sometimes referred to as ADRFs (Soltis and Cassis, 1991; 
Lohn et al., 2002; Verlohren et al., 2004). 
Diverse signalling mechanisms have been proposed, including endothelial NO release, cGMP 
generation, reactive oxygen species, and opening of various K+ channel subtypes, but independent of 
COX products or sympathetic nerves (Gollasch, 2012 and Withers et al., 2014). Accumulating 
evidence suggests that the anti-contractile effect of PVAT relies on smooth muscle K+ channels. 
Specifically, activation of voltage-gated K+ channels (KV7) and Ca
2+-activated K+ channels (BKCa) 
through endothelium-independent and -dependent pathways respectively. Interestingly, in healthy 
rat coronary septal arteries, increases in PVAT mass also reduces Rho kinese-dependent Ca2+ 
sensitivity in vascular smooth muscle (Aalbaek et al., 2015). This contrasts the observation that PVAT 
from pig coronary artery enhances vasocontraction via Rho kinase (Owen et al., 2013).   
As for a pathological role, a loss or reduced relaxant effect of PVAT is often reported in 
disease states. In spontaneously hypertensive rats, there is a loss of anti-contractile effect in 
mesenteric arteries possibly due to downregulation of KV7 channels in vascular smooth muscle or 
reduced PVAT production of Ang 1-7, one of the ADRF candidates (Galvez et al., 2006; Galvez-Prieto 
et al., 2008b; Li et al., 2013). In experimental models of obesity and metabolic syndrome, increases 
in PVAT-derived leptin (Gill-Ortega et al., 2009), superoxide, hydrogen peroxide (Gao et al., 2005a; 
Rebolledo et al., 2010; Ketonen et al., 2010; Aghamohammadzadeh et al., 2016) or free fatty acid 
level (Sun et al., 2013) also play a role in aorta, mesenteric or subcutaneous arteries. Although PVAT 
produce the vasorelaxants adiponectin and NO, obesity is associated with reduced PVAT adiponectin 
and reduced endothelial NO release and bioavailability, partly due to oxidative stress (c.f. Figure 2). 
For example, in rodent mesenteric arteries, this can be rescued by superoxide dismutase and 
catalase, which remove superoxide and hydrogen peroxide respectively, or anti-oxidants (Marchesi 
et al., 2009; Aghamohammadzadeh et al., 2016). Despite an upregulation of leptin, there is an 
impairment of leptin-induced NO release from the endothelium in hypertension and obesity models 
(Beltowski et al., 2003; Rahmouni et al., 2005; Galvez-Prieto et al., 2012). This implicates PVAT in 
vascular leptin-resistance, which exacerbates the cardiovascular complications associated with 
obesity.  
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Other data suggest that, in obesity and diabetes, downregulation of PVAT-derived 
adiponectin might lead to upregulation of superoxide and TNFα, and reduced endothelial NO 
production and relaxation (c.f. Table 2; Virdis et al., 2015; Hou et al., 2016; Nacci et al., 2016). It is 
often unclear why PVAT-derived relaxants are downregulated in disease states, but hypoxia in PVAT 
might be a contributing factor (Withers et al., 2011). A local reduction of PVAT adiponectin (Virdis et 
al., 2015; Aghamohammadzadeh et al., 2016) without concomitant changes in its circulatory levels is 
also evident in human obesity (Dreier et al., 2016). Of particular relevance to insulin resistance and 
diabetes, adiponectin is known to activate AMP-activated protein kinase (AMPK), a key intracellular 
energy sensor that improves insulin sensitivity and modulate adipocyte metabolism and 
inflammation (see Almabrouk et al., 2014 for reivew). AMPK in endothelium and vascular smooth 
muscle also regulates vascular tone and remodelling (Ma et al., 2010; Meijer et al., 2013; Almabrouk 
et al., 2014), and probably contribute to the cardiovascular benefits of the anti-diabetic drugs, 
glitazones which are Peroxisome Proliferator-Activated Receptor gamma (PPAR) agonists and AMPK 
activators. Interestingly, a recent study suggests that AMPK in PVAT is required for the secretion of 
adiponectin in mouse aorta (Almabrouk et al., 2016), providing a molecular mechanism for cross-
talks with hypoxia and other PVAT-derived vasoactive substances that activate or inhibit AMPK 
(Almabrouk et al., 2014; Virdis et al., 2015).  
 
Anti-contractile versus pro-contractile effects of PVAT 
The co-existence of pro-contractile and anti-contractile actions of PVAT may seem contradictory but 
such dual effects have also been demonstrated in the same arteries and within the same studies 
(Soltis and Cassis, 1991; Lohn et al., 2002; Ketonen et al., 2010; Li et al., 2013; Aalbaek et al., 2015). 
Indeed, some of the PVAT-derived factors such as leptin, TNFα, IL-6 and hydrogen peroxide are 
known to have both contractile and relaxant properties (Brian and Faraci, 1998; Orshal and Khaliil, 
2004; Thakali et al., 2006; Virdis et al., 2015). Upregulation or downregulation of these factors can 
also compromise endothelial function (c.f. Table 2). It is therefore not surprising that the balance 
between pro-contractile and anti-contractile function, and how it is altered in disease conditions is 
under increasingly intense investigations.  
Both relaxant and contractile actions of PVAT effects are detectable in healthy conditions, at 
least in thoracic aorta, mesenteric and coronary artery (Soltis and Cassis, 1991; Dubrovska et al., 
2004; Verlohren et al. 2004; Payne et al., 2010). Many studies have proposed a predominantly anti-
contractile action in health, although it is possible that the net effect on vascular tone depends on 
the anatomical location and experimental conditions used. As discussed in the previous section, 
systemic arteries (including mesenteric artery, thoracic and abdominal aorta) and coronary arteries 
often show a reduced production or responsiveness to PVAT-derived relaxants or other 
vasorelaxants in hypertension, obesity and diabetes. This, together with an underlying contraction 
induced by PVAT, which can also be enhanced in some forms of hypertension and obesity (c.f. Table 
1), would promote a net contractile action of PVAT (Figure 1). This may result in sustained 
vasoconstriction. Indeed, PVAT dysfunction is correlated with raised arterial blood pressure in obese 
rats (Aghamohammadzadeh et al., 2016). Genetic deletion of PPAR in mouse perivascular 
adipocytes during development results in the absence of PVAT and hypotension, pointing to a key 
role for PVAT in blood pressure regulation (Chang et al., 2012). However, we are yet to fully 
understand how PVAT function transitions from health to disease, and how best to reverse the 
  
This article is protected by copyright. All rights reserved. 
adverse effects of PVAT. In the case of obesity, weight loss through bariatric surgery or caloric 
restriction might reduce PVAT inflammation and improve NO bioavailability, resulting in normalised 
blood pressure (Aghamohammadzadeh et al., 2013; Bussey et al., 2016). 
 
Interactions between adipocytes and immune cells in PVAT  
Aside from vascular reactivity, many of the PVAT-derived mediators are also critical players in 
vascular inflammation. Evidence suggests that a pro-inflammatory phenotype of PVAT is a common 
feature of hypertension, obesity, insulin resistance and atherosclerosis (Chatterjee et al., 2009; 
Omar et al., 2014; Almabrouk et al., 2014; Mikolajczyk et al., 2016). Adipocytes are the main 
component in PVAT, but immune cells such as macrophages and T-lymphocytes also play an 
important role in regulating PVAT function, and provide an alternative source of vasoactive 
mediators. As part of the pathological remodelling of adipose tissues, obese rodents and humans 
have a higher PVAT mass and adipocyte hypertrophy (Marchesi et al., 2009; Ma et al., 2010; 
Greenstein et al., 2009). The hypertrophied PVAT likely exceeds the diffusion limit of oxygen and 
suffers from hypoperfusion, leading to local hypoxia (Hosogai et al.., 2007; Greenstein et al., 2009). 
The hypoxic state is linked to increased expression of the chemokine MCP-1 in PVAT, which in turn 
promotes recruitment and infiltration of macrophages, which act as a major source of TNF (see 
Gustafson et al., 2007 for review; Ketonen et al., 2010). Through upregulation of the other 
chemokines IL-8 and RANTES in PVAT and superoxide in PVAT and vascular cells (Table 2), PVAT also 
stimulates recruitment of monocytes and lymphocytes in arteries from models of obesity, 
hypertension or metabolic syndrome (Henrichot et al., 2005; Marchesi et al., 2009; Mikolajczyk et 
al., 2016). Figure 2 illustrates how dysregulation of PVAT-derived factors might occur in these 
disease states. 
At the same time, there is an upregulation of pro-inflammatory mediators (e.g. TNF and IL-
6) and a downregulation of anti-inflammatory mediators (e.g. adiponectin and IL-10), from 
adipocytes and macrophages (Greenstein et al., 2009; Chatterjee et al., 2009; Lumeng et al., 2007). 
The resultant pro-inflammatory phenotype has been linked to the loss of PVAT-induced relaxation 
and this deficit may be partially reversed by TNF antagonists or IL-6 antibodies (Greenstein et al., 
2009; Ozen et al., 2015; Aghamohammadzadeh et al., 2016). Endothelium-dependent relaxation is 
also likely compromised by PVAT-derived TNFα and reactive oxygen species (Virdis et al., 2015). In 
macrophage-deficient mice, the ability of hypoxia to inhibit PVAT relaxation is greatly reduced, 
supporting a key role for PVAT macrophages (Withers et al., 2011). In addition, there is an 
accumulation of leukocytes in PVAT, so much so that deficiency in P-selectin glycoprotein ligand-1 
(Psgl-1), a ligand essential for leukocyte attachment and rolling at the endothelium, prevents 
endothelial dysfunction and inflammation induced by PVAT in obese mice (Wang et al., 2012).  
In contrast to the case for obesity, the size of PVAT adipocytes and PVAT mass are often 
reduced in experimental models of hypertension, including spontaneously hypertensive and DOCA-
salt hypertensive rats (Galvez et al., 2006; Ruan et al., 2010). Despite this, a recent study has 
demonstrated that Ang II-induced hypertension increases PVAT expression of RANTES, resulting in 
increased T-lymphocyte infiltration and impaired endothelium-dependent relaxation (Mikolajczyk et 
al., 2016; Figure 2). It should be noted that whilst adipokines such as chemerin, adiponectin and 
leptin are released from PVAT adipocytes, many of the PVAT-derived chemokines, cytokines and 
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reactive oxygen species might be produced by multiple cell types within PVAT, including adipocytes 
and immune cells (see also Szasz et al., 2013 and Pellegrinelli et al., 2016 for reviews). Furthermore, 
vascular cells produce some of the same pro- or anti-inflammatory mediators from PVAT, and also 
express receptors for these mediators. Therefore, the interplay among adipocytes, infiltrated 
immune cells and vascular cells would need to be further explored.  
 
PVAT dysfunction in humans  
The past ten years have seen growing interests in PVAT dysfunction. Whilst the current data on 
human PVAT remain limited, they broadly agree with those obtained in animal models. For instance, 
anti-contractile effects of PVAT is compromised in small arteries of patients with metabolic 
syndrome or obesity (Greenstein et al., 2009; Aghamohammadzadeh et al., 2013), and that human 
PVAT shows distinctive expression pattern of pro-inflammatory mediators, including IL-6, MCP-1 and 
leptin, compared to subcutaneous adipose tissue (Rittig et al., 2012; Mauro et al., 2013). However, 
the functional significance of various ADCFs and ADRFs may differ. For example, adiponectin appears 
to play a more important role in PVAT relaxation in humans than in rodents (Fesus et al., 2007; 
Greenstein et al., 2009; Meijer et al., 2013). In patients undergoing coronary bypass surgery, initial 
experiments suggest that saphenous vein graft with intact adventitia and PVAT, as opposed to a 
conventional free graft, reduces vasospasm and potentially improves its patency (Dashwood et al., 
2009). Thus, it might be concluded that PVAT exerts a predominantly anti-contractile effects in 
humans. In contrast, individuals with more PVAT in brachial artery has diminished hyperaemic blood 
flow (Rittig et al., 2008), suggesting a basal contractile influence of PVAT. Further characterisation of 
PVAT-derived factors from different vascular regions are needed. Thus far, mechanistic studies have 
been performed on the more accessible vessels from volunteers, namely the internal thoracic artery 
(Gao et al., 2005a; Malinowski et al., 2008), small arteries in gluteal fat (Greenstein et al., 2009; 
Aghamohammadzadeh et al., 2013) and saphenous veins (Dashwood et al., 2009).  
The Framingham Heart Study reported a correlation between periaortic fat mass and 
hypertension or diabetes irrespective of the body mass index, but a causal relationship is yet to be 
established (Lehman et al., 2010; Britton et al., 2012). In addition to reduced body weight, bariatric 
surgery in severely obese patients has been shown to restore PVAT-induced relaxation, improve 
inflammatory cytokines profile and NO bioavailability, and reduce macrophage infiltration and 
systolic blood pressure (Aghamohammadzadeh et al., 2013). More recently, in diet-induced obese 
rats, calorie restriction and sustained weight loss has similarly been found to reverse PVAT-mediated 
vascular damage (Bussey et al., 2016). These data support the contribution of PVAT dysfunction to 
the pathogenesis of obesity and metabolic syndrome. Elevated circulatory level of chemerin also 
correlates with impaired endothelial function and increased arterial stiffness in hypertensive 
patients (Gu et al., 2015). The specific role played by PVAT relative to other fat depots merits further 
investigations, particularly in view of the differential responses to high fat diet in white and brown 
adipocytes (Fitzgibbons et al., 2011). 
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When assessing data from animal and human experimental studies, it is also important to 
consider the effect of ageing, an independent risk factor for cardiovascular diseases. Ageing 
exacerbates aorta PVAT dysfunction, with increases in oxidative stress and macrophage infiltration, 
and a pro-inflammatory secretion pattern of cytokines and chemokines (Bailey-Downs et al., 2013; 
Mauro et al., 2013; Fleenor et al., 2014). This effect is at least partly mimicked by medium 
conditioned with aged aorta PVAT, and is accompanied by endothelial dysfunction in aorta, 
especially in diet-induced obese mice (Bailey-Downs et al., 2013). Thus, PVAT may also contribute to 
the endothelial dysfunction and vascular remodelling seen in ageing. On the other hand, PVAT 
relaxation is inhibited in ageing mice (Agabiti-Rosei et al., 2017), hinting at an overall pro-contractile 
action of PVAT during ageing. Further investigations will need to clarify the PVAT function in healthy 
versus pathological ageing. It is also worth noting that the age of rodent models of obesity vary (Lutz 
and Woods, 2012) and are generally younger than subjects of clinical studies.  
 
Conclusion  
In this review, we have focused on the effects of PVAT on vascular tone regulation. It is apparent 
that PVAT exerts both contractile and relaxant actions through the release of autocrine/paracrine 
factors from adipocytes and infiltrating inflammatory cells in PVAT (Figure 1). PVAT is therefore an 
integral part of vascular function, including cross-talk with the endothelium, smooth muscle, 
immune cells and perivascular nerves. The balance between pro-contractile and anti-contractile 
effects maybe tissue-specific but modulation by obesity and hypertension induces a shift towards a 
pro-contractile, pro-inflammatory and pro-oxidative phenotype (Figure 2). This PVAT dysfunction 
may also occur in other obesity-related disorders, including metabolic syndrome, diabetes and 
atherosclerosis. However, despite a much better knowledge on the structure and function of PVAT, 
there are still many unanswered questions. The molecular mechanisms that regulate PVAT quantity 
and composition, and secretion of vasoactive factors in health and disease, which likely exist in a 
continuum, remain elusive. Although there is experimental evidence for PVAT dysfunction in the 
pathogenesis of hypercontractility in disease states, it is also possible that it has a protective and 
adaptive role in vascular homeostasis. Moreover, the function of PVAT relative to the systemic 
influence of visceral and subcutaneous fat remains to be clarified. Given the heterogeneity in PVAT 
function in different anatomical regions and species, more studies using human tissues are required.  
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Table 1.   PVAT-derived contractile factors. Studies that demonstrate PVAT production of mediators, 
which either induce direct contraction or potentiate contractions to other vasoconstrictors, are 
highlighted.  
, increase; , lead to; ACE, angiotensin-converting enzyme; Ang II, angiotensin II; COX, 
cyclooxygenase; DOCA, deoxycorticosterone acetate; eNOS, endotheliual nitric oxide synthase; ERK, 
extracellular signal-regulated kinase; ET1, endothelin-1; ETA, endothelin ETA receptor; NADPH 
oxidase, nicotinamide adenine dinucleotide phosphate oxidase; NO, nitric oxide; PGE2, prostaglandin 
E2; PVAT, perivascular adipose tissue; SHRSP, stroke-prone spontaneously hypertensive rat; 
thromboxane A2, TXA2; TNF α, tumour necrosis factor-α  
Contractile 
factor 
PVAT expression Effect Vascular bed Reference 
Ang II Ang II protein; 
angiotensinogen 
and ACE mRNA in 
PVAT adipocytes 
 Sympathetic contraction  Rat superior 
mesenteric artery 
Lu et al., 
2010 
Ang II protein, 
angiotensinogen, 
ACE and chymase 
mRNA  
 Rat thoracic aorta 
 
Rat (resistance) 
mesenteric artery 
Galvez-Prieto 
et al., 2008a 
 
Superoxide  Superoxide; 
NADPH oxidase 
protein in PVAT 
adipocytes  
 Sympathetic contraction 
(via tyrosine kinase and ERK, 
but independent of NO) 
Rat superior 
mesenteric artery 
Gao et al., 
2006 
Catecholamines Noradrenaline 
and adrenaline in 
PVAT adipocytes 
Contraction  Rat thoracic aorta 
 
Rat superior 
mesenteric artery 
Ayala-Lopez 
et al., 2014 
Noradrenaline 
from sympathetic 
nerve endings 
Contraction Rat thoracic aorta 
 
Soltis and 
Cassis, 1991 
Prostanoids TXA2 in PVAT-
conditioned 
buffer; COX-1 and 
COX-2 mRNA  
 Agonist-induced 
contraction (independent of 
NOS or ETA).  
Mouse thoracic 
aorta (only in 
monogenic obesity 
and diet-induced 
obesity) 
Meyer et al., 
2013 
PGE2 in PVAT (or 
PVAT-conditioned 
buffer) 
Contraction Rat mesenteric 
artery 
Mendizabal 
et al., 2013;  
TNFα 
 
TNFα protein in 
PVAT adipocytes 
 
 Contraction to eNOS 
inhibition 
 
 ET-1 and NADPH oxidase-
derived superoxide in 
Human small 
arteries from 
visceral fat 
(enhanced in obese 
patients) 
Virdis et al., 
2015 
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vascular cells 
IL-6 IL-6 in PVAT 
adipocytes 
 Human coronary 
artery (enhanced 
with high fat diet) 
Chatterjee et 
al., 2009 
Chemerin Chemerin protein 
in PVAT 
adipocytes 
Contraction 
  
 agonist-induced 
contraction (enhanced by 
endothelial removal or NOS 
inhibition) 
 
Rat thoracic aorta 
 
Rat superior 
mesenteric artery  
 
(enhanced 
responses in DOCA-
salt hypertensive 
but not diet-
induced obese or 
SHRSP rats) 
Watts et al., 
2013 
Chemerin protein 
in PVAT 
adipocytes 
Contraction 
 
 agonist-induced 
contraction 
Human resistance 
mesenteric artery  
Watts et al., 
2013 
Chemerin protein 
in PVAT 
adipocytes 
 Sympathetic contraction Rat superior 
mesenteric artery 
Darios et al., 
2016 
Leptin (PVAT-
conditioned 
buffer) 
 Agonist- and 
depolarisation-induced 
contraction (via increased 
voltage-gated Ca2+ entry) 
 
 Smooth muscle 
proliferation 
Pig coronary artery 
(enhanced in diet-
induced obesity) 
Owen et al., 
2013; Noblet 
et al., 2016 
  
This article is protected by copyright. All rights reserved. 
Table 2.   Inhibitory effect of PVAT on endothelium-dependent relaxation. This is often 
demonstrated by studying the effects of PVAT on responses to endothelium-dependent relaxants 
that are applied to isolated arteries or isolated vascular cells. Upregulation or downregulation of 
PVAT-derived factors are thought to exaggerate the reduction in endothelium-dependent relaxation 
in disease states. However, in some studies the diffusible factors responsible for the inhibitory 
effects of PVAT on endothelial function are not identified. 
, increase; , decrease; , lead to; AMPK, adenosine monophosphate-activated protein kinase; 
AT1, angiotensin II receptor type 1; eNOS, endothelial nitric oxide synthase; ET-1, endothelin-1; IRS-
1, insulin receptor substrate-1; MCP-1, monocyte chemoattractant protein-1; mTOR, mechanistic 
target of rapamycin; NADPH oxidase, nicotinamide adenine dinucleotide phosphate oxidase; NO, 
nitric oxide; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C, PVAT, perivascular adipose 
tissue; TNFα, tumour necrosis factor-α; RANTES, regulated on activation, normal T cell expressed and 
secreted 
PVAT-derived 
factor  
Proposed mechanism of 
inhibition 
Endothelium-
dependent 
relaxant 
affected 
Vascular bed Reference 
Resistin 
 
 IRS-1 and PI3K activity in 
endothelium   eNOS 
activity 
 
Insulin  Mouse aorta 
Mouse mesenteric 
artery 
Gentile et al., 
2008 
 Endothelial superoxide  
 eNOS expression 
Bradykinin  Pig coronary artery Kougias et 
al., 2005 
Adiponectin   Adiponectin in PVAT  
 AMPK and Akt 
phosphorylation 
Insulin  Mouse resistance 
artery from skeletal 
muscle  
(only in genetic model 
of obesity and Type 2 
diabetes) 
Meijer et al., 
2013 
Unknown  AMPK phosphorylation  
mTOR phosphorylation     
 eNOS expression  
Acetylcholine Rat thoracic aorta and 
mesenteric artery 
(only in diet-induced 
obesity) 
Ma et al., 
2010 
Leptin   Leptin in PVAT and  leptin 
receptor expression   PKCβ 
activity in vascular cells  
 
Bradykinin Pig coronary artery  
(only in obesity with 
metabolic syndrome) 
Payne et al., 
2010 
Unknown  PKCβ-mediated eNOS 
phosphorylation   
endothelial NO  
Bradykinin Dog coronary artery  Payne et al., 
2008;  Payne 
et al., 2009 
Unknown  Endothelial Ca2+ signal Acetylcholine 
Methacholine 
 
Rat coronary septal 
artery 
Aalbaek et 
al., 2015 
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Unknown (but 
independent 
of superoxide, 
prostanoids,  
ET-1 and AT1) 
 Endothelial caveolin-1      
 NO production  
 
Acetylcholine Rat thoracic aorta Lee et al., 
2014 
Superoxide 
 
Hydrogen 
peroxide  
 
Leptin 
 
MCP-1 
 Superoxide, hydrogen 
peroxide, leptin and MCP-1 in 
PVAT 
 
Acetylcholine Mouse abdominal 
aorta  
(only in diet-induced 
obesity) 
Ketonen et 
al., 2010 
Visfatin  NADPH oxidase activity in 
vascular cells   endothelial 
NO 
Bradykinin or 
acetylcholine  
Rat and human 
resistance mesenteric 
arteries 
Vallejo et al., 
2011 
TNFα 
 
Adiponectin  
 TNFα and  adiponectin 
in PVAT  NADPH oxidase 
activation   eNOS 
expression   basal 
endothelial NO  
 
 superoxide and ET-1 in 
vascular cells  
 Human small arteries 
from visceral fat 
(enhanced effects in 
obesity) 
Virdis et al., 
2015 
RANTES   RANTES   T-lymphocytes 
in PVAT but not visceral fat  
 
 Ang II-induced superoxide 
production in vascular cells 
Acetylcholine Mouse thoracic and 
abdominal aorta  
(enhanced in Ang II-
induced hypertension) 
Mikolajczyk 
et al., 2016 
 
  
This article is protected by copyright. All rights reserved. 
 
 
Figure 1.   Regulation of vascular tone by PVAT in health and disease. (A) PVAT releases a diverse 
group of bioactive and diffusible substances, including leptin, adiponectin, angiotensin II, angiotensin 
1-7, catecholamines, reactive oxygen species, nitric oxide, hydrogen sulphide, cytokines such as 
tumour necrosis factor- and interleukin-6, and chemokines such as MCP-1 and RANTES. These 
mediators modulate vascular tone through a paracrine action on the endothelium, vascular smooth 
muscle and immune cells. The chemokines and cytokines regulate migration of immune cells into 
PVAT, and activated macrophages and lymphocytes within PVAT can also release additional 
cytokines. (B) In healthy conditions, PVAT tends to exert a net anti-contractile effect. 
Pathophysiological stimuli for example in obesity, hypertension and diabetes alter the secretary 
pattern of PVAT, leading to increased pro-contractile and decreased anti-contractile actions. This 
imbalance is characteristic of PVAT dysfunction in disease states. Other changes in PVAT 
composition and function include adipocyte hypertrophy, infiltration of macrophages and 
lymphocytes, and inflammation within PVAT and vascular cells. 
ADCF, adipocyte-derived contractile factor; ADRF, adipocyte-derived relaxing factor; ADV, adventitia; 
EC, endothelium; PVAT, perivascular adipose tissue; SM, smooth muscle 
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Figure 2.   Proposed mechanisms of PVAT dysfunction in obesity, diabetes and hypertension. PVAT 
dysfunction is characterised by changes in its secretory pattern and increased occurrence of 
activated macrophages and lymphocytes in PVAT. In addition to adipocytes, activated immune cells 
within PVAT also release additional cytokines. In obesity and Type 2 diabetes, PVAT dysfunction is 
likely triggered by adipocyte hypertrophy and increases in PVAT mass. PVAT expansion is not a 
prerequisite for PVAT dysfunction since the size of adipocytes and overall PVAT mass maybe reduced 
in some forms of hypertension in the absence of obesity.  
Ang 1-7, angiotensin 1-7; Ang II, angiotensin II; MCP-1, monocyte chemoattractant protein-1; NO, 
nitric oxide; RANTES, regulated on activation, normal T cell expressed and secreted; 
 
